chufangao/CTO huggingface dataset:
Clinical trial NCT04324021: Efficacy and Safety of Emapalumab and Anakinra in Reducing Hyperinflammation and Respiratory Distress in Patients With COVID-19 Infection.
Official title: A Phase 2/3, Randomized, Open-label, Parallel Group, 3-arm, Multicenter Study Investigating the Efficacy and Safety of Intravenous Administrations of Emapalumab, an Anti-interferon Gamma (Anti-IFNγ) Monoclonal Antibody, and Anakinra, an Interleukin-1(IL-1) Receptor Antagonist, Versus Standard of Care, in Reducing Hyper-inflammation and Respiratory Distress in Patients With SARS-CoV-2 Infection.
Sponsor: Swedish Orphan Biovitrum (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: TERMINATED 
Why stopped: Standard of care evolved during the timeframe of the study and had critical impact on recruitment.~Early termination was not based on safety reasons but due to the reasons mentoined above.~The ongoing patients were completed.
Enrollment: 16.0 (ACTUAL)
Number of arms: 3.0
Start date: 2020-04-02
Primary completion date: 2020-11-13
Completion date: 2020-11-13
Plan to share individual participant data: NO
Clinical trial NCT03334435: A Study of Long-term Baricitinib (LY3009104) Therapy in Atopic Dermatitis
Official title: A Phase 3 Multicenter, Double-Blind Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Adult Patients With Atopic Dermatitis
Acronym: BREEZE-AD3
Sponsor: Eli Lilly and Company (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 1645.0 (ACTUAL)
Number of arms: 16.0
Start date: 2018-03-28
Primary completion date: 2020-09-21
Completion date: 2023-07-12
Baseline population: Modified Intent-to-treat Population: All participants who received at least one dose of investigational product (IP) in JAHN.
Plan to share individual participant data: YES
IPD sharing description: Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement.
Clinical trial NCT03648229: African Glaucoma Laser Trial
Official title: African Glaucoma Laser Trial
Acronym: AGLT
Sponsor: West Virginia University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: Funding unavailable
Enrollment: 0.0 (ACTUAL)
Number of arms: 3.0
Start date: 2019-09-01
Primary completion date: 2022-06-30
Completion date: 2024-06-30
Plan to share individual participant data: NO
IPD sharing description: To be determined by NIH Data Sharing Policy
Clinical trial NCT04176991: Single Ascending Dose Study of CTI-1601 Versus Placebo in Subjects With Friedreich's Ataxia
Official title: A Phase 1 Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CTI-1601 Versus Placebo in Subjects With Friedreich's Ataxia
Sponsor: Larimar Therapeutics, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 28.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-12-11
Primary completion date: 2020-10-31
Completion date: 2020-10-31
Clinical trial NCT03806556: A Pediatric Trial Using Tranexamic Acid in Thrombocytopenia
Official title: A Pediatric Trial Using Tranexamic Acid in Thrombocytopenia
Sponsor: University of Pittsburgh (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Low accrual rate, strategic reasons
Enrollment: 11.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-04-22
Primary completion date: 2020-08-25
Completion date: 2020-08-25
Limitations and caveats: The pre-specified analysis described in the study protocol stated the following: For secondary endpoints, events of WHO Grade 2 or higher bleeding will be compared through the use of odds ratio or T-test statistic of means. The mean number of platelet transfusions will be analyzed using a T-test statistic of means. This analysis was not completed as it would be scientifically inappropriate due to insufficient enrollment. Instead a descriptive analysis was completed.
Plan to share individual participant data: YES
IPD sharing description: Anonymized public data set will be available after publication of primary results
IPD time frame: Beginning within 1 year and ending 5 years after trial completion
IPD access criteria: Researchers who provide a methodologically sound proposal may request data. Proposals should be directed to meghan.mccormick3@chp.edu. To gain access data requestors will need to sign a data access agreement.
Clinical trial NCT03135262: A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)
Official title: A Phase Ib/II Study Evaluating the Safety and Efficacy of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Patients With Relapsed or Refractory Follicular Lymphoma and Obinutuzumab or Rituximab in Combination With Idasanutlin and Venetoclax in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Sponsor: Hoffmann-La Roche (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Sponsor's decision to terminate the study after Phase 1; will not proceed with Phase 2.
Enrollment: 29.0 (ACTUAL)
Number of arms: 4.0
Start date: 2017-06-15
Primary completion date: 2020-04-30
Completion date: 2020-04-30
Limitations and caveats: Dose expansion part of the study did not take place. AEs were not differentiated for DLBCL and FL arms since these are sub mutations of disease which does nor show differences in AEs.
Clinical trial NCT04595370: Efficacy, Safety and Tolerability of AZD9977 and Dapagliflozin in Participants With Heart Failure and Chronic Kidney Disease
Official title: A Phase 2b, Randomised, Double-Blind, Active Controlled, Multi Centre Study to Evaluate the Efficacy, Safety and Tolerability of Oral AZD9977 and Dapagliflozin Treatment in Patients With Heart Failure and Chronic Kidney Disease
Acronym: MIRACLE
Sponsor: AstraZeneca (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 153.0 (ACTUAL)
Number of arms: 4.0
Start date: 2021-01-26
Primary completion date: 2023-09-22
Completion date: 2023-09-22
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment:~https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.~Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
IPD time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Clinical trial NCT03727789: CBL0137 in Treating Patients With Advanced Extremity Melanoma or Sarcoma
Official title: A Single-Center Phase I Dose Escalation/Response Trial to Evaluate Safety, Tolerability, and Anti-Tumor Efficacy of Intra-Arterial CBL0137 for Patients With Advanced Extremity Melanoma or Sarcoma
Sponsor: Roswell Park Cancer Institute (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: low accrual
Enrollment: 7.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-07-01
Primary completion date: 2024-01-16
Completion date: 2024-01-16
Clinical trial NCT04838054: The Efficacy of Stabilized Chlorine Dioxide Rinse as a Chemical Adjuvant for Treatment of Per-implant Mucositis
Official title: Pilot Study: The Efficacy of Stabilized Chlorine Dioxide Rinse as a Chemical Adjuvant for Treatment of Peri-implant Mucositis
Sponsor: Rowpar Pharmaceuticals, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 57.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-03-15
Primary completion date: 2020-01-15
Completion date: 2020-03-04
Baseline population: The focus of the analysis is on the teeth. The study will evaluate the outcome for all teeth as well as compare the outcomes between teeth and implants.
Plan to share individual participant data: NO
Clinical trial NCT04105010: Assessing An Oral Janus Kinase Inhibitor, AZD4205 as Monotherapy in Patients Who Have PTCL (JACKPOT8)
Official title: A Phase I/II, Open-Label, Multicentre Study to Investigate the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of AZD4205 in Patients With Peripheral T Cell Lymphoma (PTCL)
Sponsor: Dizal Pharmaceuticals (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 171.0 (ACTUAL)
Number of arms: 4.0
Start date: 2019-09-10
Primary completion date: 2023-10-12
Completion date: 2024-02-22
Plan to share individual participant data: NO
Clinical trial NCT02952586: Study To Compare Avelumab In Combination With Standard of Care Chemoradiotherapy (SoC CRT) Versus SoC CRT for Definitive Treatment In Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck (JAVELIN HEAD AND NECK 100)
Official title: A RANDOMIZED DOUBLE-BLIND PHASE 3 STUDY OF AVELUMAB IN COMBINATION WITH STANDARD OF CARE CHEMORADIOTHERAPY (CISPLATIN PLUS DEFINITIVE RADIATION THERAPY) VERSUS STANDARD OF CARE CHEMORADIOTHERAPY IN THE FRONT-LINE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK
Sponsor: Pfizer (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: The trial prematurely terminated as recommended by the E-DMC because the boundary for futility has been crossed.
Enrollment: 697.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-11-28
Primary completion date: 2019-12-23
Completion date: 2020-08-25
Baseline population: The full analysis set (FAS) included all randomized participants.
Plan to share individual participant data: YES
IPD sharing description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Clinical trial NCT05129280: A Study to Evaluate Safety, Pharmacokinetics, and Preliminary Anti-tumor Activity of RO7444973 in Participants With Unresectable and/or Metastatic MAGE-A4-positive Solid Tumors
Official title: An Open-label, Multicenter, Phase I Study to Evaluate Safety, Pharmacokinetics, and Preliminary Anti-tumor Activity of RO7444973 in Participants With Unresectable and/or Metastatic MAGE-A4-positive Solid Tumors
Sponsor: Hoffmann-La Roche (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: The study was terminated due to program discontinuation.
Enrollment: 23.0 (ACTUAL)
Number of arms: 3.0
Start date: 2022-01-25
Primary completion date: 2023-07-12
Completion date: 2023-07-12
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).
Clinical trial NCT04490486: Umbilical Cord Tissue (UC) Derived Mesenchymal Stem Cells (MSCs) Versus Placebo to Treat Acute Pulmonary Inflammation Due to COVID-19
Official title: Phase I, Randomized, Double Blinded, Placebo Control Study to Evaluate the Safety and Potential Efficacy of Intravenous Infusion of Umbilical Cord Tissue (UC) Derived Mesenchymal Stem Cells (MSCs) Versus Placebo to Treat Acute Pulmonary Inflammation Due to COVID-19 With Moderate to Severe Symptoms
Acronym: COVID-19
Sponsor: University of Miami (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Not Funded
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-10-01
Primary completion date: 2024-06-01
Completion date: 2024-06-01
Plan to share individual participant data: NO
Clinical trial NCT03668808: Comparison of Insulin Degludec With Insulin Glargine U100 for Adults With Type 1 Diabetes Crossing Multiple Time Zones.
Official title: Comparison of Insulin Degludec With Insulin Glargine U100 for Adults With Type 1 Diabetes Travelling Across Multiple Time Zones. A Pilot Study.
Acronym: SafrTravlT1D
Sponsor: Sansum Diabetes Research Institute (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 25.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-11-16
Primary completion date: 2020-09-19
Completion date: 2020-09-19
Baseline population: Subjects randomly assigned to one arm and then crossed over to the other arm when the first was completed.
Plan to share individual participant data: UNDECIDED
IPD sharing description: Undecided to whether to make individual participant data available.
Clinical trial NCT04095793: Phase 3 Open-Label Extension Study of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure
Official title: A Phase 3, 182-week, Open-Label, Extension Study to Investigate the Safety and Tolerability of TD-9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension (Symptomatic nOH) in Subjects With Primary Autonomic Failure
Acronym: OAK
Sponsor: Theravance Biopharma (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Stopped early due to company decision. Company decision based on analysis results in TD-9855-0169.
Enrollment: 110.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-09-19
Primary completion date: 2021-11-12
Completion date: 2021-11-12
Baseline population: The safety analysis set was defined as all enrolled participants who have received at least one dose of ampreloxetine in this study.
Limitations and caveats: Because the study was terminated early by the Sponsor, the latest scheduled study visit completed by any participant was at Week 98.
Plan to share individual participant data: NO
IPD sharing description: Theravance Biopharma, Inc. will not be sharing individual de-identified participant data or other relevant study documents.
Clinical trial NCT05345938: A Study of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Acute Myeloid Leukemia
Official title: A Phase I/II Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Acute Myeloid Leukemia
Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Adjust the research strategy.
Enrollment: 1.0 (ACTUAL)
Number of arms: 1.0
Start date: 2022-06-14
Primary completion date: 2022-11-19
Completion date: 2022-11-19
Clinical trial NCT04260529: CyPep-1 Injections in Cancer Inducing Lymphocyte Infiltrate Accumulations
Official title: A First-in-human, Open-label Dose Escalation Followed by Dose Expansion Phase I/IIa Trial to Evaluate the Safety, Preliminary Efficacy and Pharmacokinetics of Intratumoral CyPep-1 Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Cancers.
Acronym: CICILIA
Sponsor: Cytovation AS (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: COMPLETED 
Enrollment: 60.0 (ACTUAL)
Number of arms: 4.0
Start date: 2020-04-30
Primary completion date: 2024-07-05
Completion date: 2024-07-05
Plan to share individual participant data: YES
IPD sharing description: De-identified data for all primary and secondary outcomes will be made available.
IPD time frame: Within 6 months of study completion
Clinical trial NCT03106428: A Multiple Ascending Dose Study of MEDI7247 in Patients With Selected Relapsed/Refractory Hematological Malignancies
Official title: A Phase 1 Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Antitumor Activity of MEDI7247 in Patients With Selected Relapsed/Refractory Hematological Malignancies
Sponsor: MedImmune LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 67.0 (ACTUAL)
Number of arms: 3.0
Start date: 2017-03-29
Primary completion date: 2020-01-03
Completion date: 2020-01-03
Plan to share individual participant data: UNDECIDED
Clinical trial NCT04683224: A Study to Evaluate the Safety, Immunogenicity, and Efficacy of UB-612 COVID-19 Vaccine
Official title: A Phase 2/3 Randomized, Multicenter, Double-Blind, Placebo Controlled, Dose-Response Study to Evaluate the Safety, Immunogenicity, and Efficacy of UB-612 Vaccine in Adults
Sponsor: Vaxxinity, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: WITHDRAWN 
Why stopped: Study was withdrawn due to redesign of the protocol.
Enrollment: 0.0 (ACTUAL)
Number of arms: 8.0
Start date: 2021-02-01
Primary completion date: 2023-03-22
Completion date: 2023-03-22
Plan to share individual participant data: NO
Clinical trial NCT03737448: TRimetazidine for acUte on Chronic Liver Failure STudy
Official title: A Phase 1b Open-Label Study Assessing the Pharmacokinetics, Tolerability, and Safety of Oral Trimetazidine in Subjects With Acute-on-Chronic Liver Failure
Acronym: TRUST
Sponsor: Martin Pharmaceuticals (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: SUSPENDED 
Why stopped: Lack of enrollment
Enrollment: 30.0 (ESTIMATED)
Number of arms: 2.0
Start date: 2018-11-28
Primary completion date: 2021-06-30
Completion date: 2021-06-30
Plan to share individual participant data: NO
Clinical trial NCT02912182: Acute Unilateral Vestibulopathy and Corticosteroid Treatment
Official title: Acute Unilateral Vestibulopathy and Corticosteroid Treatment
Sponsor: Lund University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Placebo medication expired
Enrollment: 78.0 (ACTUAL)
Number of arms: 3.0
Start date: 2015-12-31
Primary completion date: 2021-03-01
Completion date: 2021-03-01
Plan to share individual participant data: NO
Clinical trial NCT01642004: Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC) (CheckMate 017)
Official title: An Open-Label Randomized Phase III Trial of BMS-936558 (Nivolumab) Versus Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC)
Sponsor: Bristol-Myers Squibb (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 272.0 (ACTUAL)
Number of arms: 2.0
Start date: 2012-10-16
Primary completion date: 2014-11-17
Completion date: 2021-08-16
Baseline population: All randomized participants
Clinical trial NCT03074786: Reversing the Epidemic in Africa With Choices in HIV Prevention (REACH)
Official title: A Phase 2a Crossover Trial Evaluating the Safety of and Adherence to a Vaginal Matrix Ring Containing Dapivirine and Oral Emtricitabine/Tenofovir Disoproxil Fumarate in an Adolescent and Young Adult Female Population
Sponsor: International Partnership for Microbicides, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Study was transferred to partner who will conduct under its own IND
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-11-30
Primary completion date: 2018-12-31
Completion date: 2020-12-30
Plan to share individual participant data: NO
Clinical trial NCT02220894: Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042)
Official title: A Randomized, Open Label, Phase III Study of Overall Survival Comparing Pembrolizumab (MK-3475) Versus Platinum Based Chemotherapy in Treatment Naïve Subjects With PD-L1 Positive Advanced or Metastatic Non-Small Cell Lung Cancer (Keynote 042)
Sponsor: Merck Sharp & Dohme LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 1274.0 (ACTUAL)
Number of arms: 2.0
Start date: 2014-10-30
Primary completion date: 2018-09-04
Completion date: 2022-09-12
Baseline population: The Baseline Analysis Population consisted of all randomized participants who were alive at the time of randomization and had a Tumor Proportion Score (TPS) ≥1%.
Plan to share individual participant data: YES
IPD sharing description: http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Clinical trial NCT04269993: Impact of Cannabis on Pain and Inflammation Among Patients With Rheumatoid or Psoriatic Arthritis
Official title: Impact of Acute Cannabis Administration on Pain Symptomology and Inflammatory Markers Among Patients With Rheumatoid or Psoriatic Arthritis
Sponsor: Brown University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Termination of study funding
Enrollment: 4.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-05-18
Primary completion date: 2023-07-31
Completion date: 2023-07-31
Plan to share individual participant data: NO
Clinical trial NCT03744247: Lenvatinib Plus PD-1 Antibody Versus Lenvtinib Alone for Advanced HCC
Official title: Lenvatinib Plus Programmed Cell Death Protein-1 (PD-1) Inhibitor Versus Lenvtinib Alone for Advanced Hepatocellular Carcinoma: a Multicentre Randomised Controlled Trial
Sponsor: Sun Yat-sen University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: No paritcipants enrolled
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-04-21
Primary completion date: 2021-01-01
Completion date: 2021-06-01
Clinical trial NCT04542057: A Phase 3 Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD
Official title: A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ensifentrine Over 24 Weeks in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
Sponsor: Verona Pharma plc (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 790.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-09-22
Primary completion date: 2022-05-03
Completion date: 2022-07-06
Baseline population: All patients randomized set included all patients in the enrolled set who were randomized to study medication.